non-invasive sagging skin treatment glp-1 no downtime Quantum RF Tightening- Surgical results with The formula works across four key dimensions to visibly improve signs of facial deflation What You Should Know About

Abbass NJ, Nahlawi R, Shaia JK, Allan KC, Kaelber DC, Talcott KE, et al

Trial Structure Duration: 48 weeks of treatment Participants: 338 adults randomized 2:1:1:1:1:2:2 to placebo or retatrutide groups Doses tested: 1mg, 4mg, 8mg, 12mg (all with slow titration from 2mg starting dose) Lifestyle intervention: All participants received counseling on diet (500 kcal/day deficit) and exercise (150 min/week) Primary endpoint: Percent weight change at 24 weeks Key secondary endpoints: Weight change at 48 weeks, proportion achieving 5%, 10%, 15% loss The trial used a slow titration protocol to minimize side effects: all groups except the 1mg dose started at 2mg weekly and escalated every 4 weeks

Ro is a digital health clinic offering a focused, full-service program for GLP-1 weight-loss treatment

Based on class effects observed with approved agents and general clinical reasoning, certain patient groups may warrant closer monitoring during any future clinical use of retatrutide